Tenderwize
Wróć do wyszukiwania

Non-exclusive discount agreements for pharmaceuticals from August 2026

GWQ ServicePlus AG·Düsseldorf, Germany·Deadline May 10, 2028 · 573 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V ab dem 01.08.2026

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

30 / 100

Czynniki ryzyka

No estimated contract value or indication of expected discount/rebate is provided. This makes commercial assessment imp...

Structured data indicates the contract is EU-funded, while the XML notice states 'no-eu-funds'. This may affect complia...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Najważniejsze informacje

Zamawiający
GWQ ServicePlus AG
Kraj
Niemcy
CPV
33600000 - Pharmaceutical products
Termin
May 10, 2028

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 2 lots
  • Duration until Jun 2028
  • Conclusion of non-exclusive discount agreements for the supply of pharmaceutical products with active substances Desvenlafaxin and Perampanel.
  • Agreements are open to all interested pharmaceutical companies (admission model).
Pokaż pełne podsumowanie

Non-exclusive discount agreements for pharmaceutical products (Desvenlafaxin and Perampanel) under German social law §130a Abs. 8 SGB V. The GWQ ServicePlus AG acts on behalf of health insurance funds. The procedure follows an admission model (Zulassungsmodell) where any interested pharmaceutical company can join at any time under the same conditions. The contracts start on 01.08.2026 and run for 22 months with an option to extend by 12 months. Submission is postal. No estimated value is provided. The tender is open until 10.05.2028.

Ryzyka

No estimated contract value or indication of expected discount/rebate is provided. This makes commercial assessment imp...

Structured data indicates the contract is EU-funded, while the XML notice states 'no-eu-funds'. This may affect complia...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Pharmaceutical companies must have marketing authorization for the relevant product.

Administrative

  • Submission of signed contract in duplicate, proof of marketing authorization (AMIce database extract), signed self-declaration (Anlage 3), list of PZN (Anlage 4), and...
  • Postal submission only (electronic submission not allowed).

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

Düsseldorf, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE258895210

Działalność

Health

Części (2)

LOT-0001

Non-exclusive discount agreement for Desvenlafaxin

Non-exclusive discount agreement for the active substance Desvenlafaxin. Start date 01.08.2026, duration 22 months, extendable by 12 months. Admission model: all interested companies can join at any time. Postal submission required by 10.07.2026 for initial start.

SuppliesEU fundedElectronic submission

Lokalizacja

DEA11, Germany

Czas trwania

Jul 2026 - Jun 2028

Kategoria

Pharmaceutical products

Termin

Deadline May 10, 2028

LOT-0002

Non-exclusive discount agreement for Perampanel

Non-exclusive discount agreement for the active substance Perampanel. Start date 01.08.2026, duration 22 months, extendable by 12 months. Admission model: all interested companies can join at any time. Postal submission required by 10.07.2026 for initial start.

SuppliesEU fundedElectronic submission

Lokalizacja

DEA11, Germany

Czas trwania

Jul 2026

Kategoria

Pharmaceutical products

Termin

Deadline May 10, 2028

Szczegóły zamówienia

Data publikacji
24 Jun 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
431738-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30